Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers

BACKGROUND: Direct primary care provision of first-trimester medical abortion could potentially address inequitable abortion access in Canada. However, when Health Canada approved the combination medication Mifegymiso® (mifepristone 200 mg/misoprostol 800 mcg) for medical abortion in July 2015, we h...

Descripción completa

Detalles Bibliográficos
Autores principales: Devane, Courtney, Renner, Regina M., Munro, Sarah, Guilbert, Édith, Dunn, Sheila, Wagner, Marie-Soleil, Norman, Wendy V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839244/
https://www.ncbi.nlm.nih.gov/pubmed/31720004
http://dx.doi.org/10.1186/s40814-019-0520-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839244/
https://www.ncbi.nlm.nih.gov/pubmed/31720004
http://dx.doi.org/10.1186/s40814-019-0520-8

Ejemplares similares